Orthocell Ltd (ASX:OCC)'s Paul Anderson tells Proactive they've has passed a key milestone by completing the 12-month follow-up of the last patient treated in the Autologous Tenocyte Injection (OrthoATI®) rotator cuff tendon study. The RC study was designed to assess the effectiveness of Ortho-ATI, compared to corticosteroids, as a non-surgical treatment to a difficult clinical problem with limited treatment options.
Orthocell looks ahead to results from OrthoATI shoulder tendon study in Q4
